Kezar Life Sciences Inc reports results for the quarter ended in March - Earnings Summary

Kezar Life Sciences

12/05/2022 22:46

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in March. The
mean expectation of six analysts for the quarter was for a loss
of 28 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 26 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kezar Life Sciences Inc shares had fallen by 66.5% this
quarter and lost 66.7% so far this year.
    * The company reported a quarterly loss of $16.02 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $19.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 09:45 p.m.  ​All
figures in US dollars unless otherwise stated